Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Synthetic Biologics Names Raymond Stapleton Senior VP Manufacturing | Contract Pharma
Breaking News, Promotions & Moves

Synthetic Biologics Names Raymond Stapleton Senior VP Manufacturing

Served most recently in leadership positions at Merck

Synthetic Biologics Inc., a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, has appointed Raymond Stapleton as senior vice president, manufacturing. Dr. Stapleton will lead the manufacturing team as the company begins to prepare for late-stage clinical trials for its irritable bowel syndrome with constipation (IBS-C) and C. difficile programs, and continues to move its monoclonal antibody (mAb) program forward to address Pertussis (whooping cough).

Dr. Stapleton is a pharmaceutical and biotechnology executive with over 15 years of experience at Merck & Co. Inc., in manufacturing, operations, quality, science, technology, engineering and process development. He most recently served as executive director, global vaccine technology and engineering. During his tenure at Merck, Dr. Stapleton contributed to the scale up, tech transfer and manufacturing product launch of multiple billion dollar franchises including Isentress (oral solid dosage for AIDs), Gardasil (HPV vaccine), Keytruda (anti-PD-1 cancer mAb therapy), and performed process development for the cholesterol lowering therapy Mevacor (lovastatin).

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters